STONY BROOK, N.Y.--(BUSINESS WIRE)--AJES LifeSciences, LLC is pleased to announce, the research project contracted by Rgenix Inc., has been published in “Cell”.
As a Contract research Organization (CRO) specialized in Oncology animal models, we are pleased to have this opportunity to work for Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics.
The latest research results published in Cell illustrates the role of RGX-104 (test compound) in stimulating anti-tumor immunity.
AJES also announces a novel technique to generate orthotopic renal carcinoma in small animal model. We successfully used this technique to transplant renal carcinoma cells in to the kidney. This model can be used to perform efficacy and metastatic studies.
AJES continues to build the momentum for the aggressive growth in Contract animal research. Separately, this year, AJES closed research agreements for pre-clinical testing with several fast growing pharmaceutical companies.
AJES LIfeSciences LLC, headquartered in Stony Brook, NY, is a USA-based firm that provides integrated R&D support in all the key areas of Pharmaceutical development. We offer proprietary orthotopic and metastatic tumor models. Our services include, whole body animal imaging, small animal ultra sound MRI, CT scan and other advanced technologies. We provide a complete array of research services as required for Investigational New Drug Applications (IND). AJES LifeSciences at Stony Brook New York is fully committed to the judicious, humane use of animals in research and development. We operate in AAALAC accredited and GLP compliant audited facilities.
Corporate Headquarters
25 Health Sciences Drive
Stony Brook,
New York 11790 USA